Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

Article  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label randomised controlled trial. Lancet. 2010;376:687–97.

Article  CAS  Google Scholar 

Hayano K, Watanabe H, Ryuzaki T, et al. Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy. Surg Case Rep. 2020;6:219.

Article  Google Scholar 

Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Onco. 2014;15:1224–35.

Article  CAS  Google Scholar 

Shitara K, Bang YJ, Iwasa N, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30.

Article  CAS  Google Scholar 

Matsumoto T, Yamamura S, Ikoma T, et al. Real-world data of trastuzumab deruxtecan for advanced gastric cancer: a multi-institutional retrospective study. J Clin Med. 2022;11:2247.

Article  CAS  Google Scholar 

Fujitani K, Yang HK, Mizusawa J, et al. Gasterctomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomized controlled trial. Lancet Oncol. 2016;17:309–18.

Article  CAS  Google Scholar 

Komatsu Y, Hironaka S, Tanizawa Y, et al. Treatment pattern for advanced gastric cancer in Japan and factors associated with sequential treatment: a retrospective administrative claims database study. Adv Ther. 2022;39:296–313.

Article  CAS  Google Scholar 

Fukuchi M, Ishiguro T, Ogat K, et al. Prognostic role of conversion surgery for unresectable gastric cancer. Ann Surg Oncol. 2015;22:3618–24.

Article  Google Scholar 

Oki E, Tokunaga S, Emi Y, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2016;19:968–76.

Article  Google Scholar 

Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329–38.

Article  Google Scholar 

Kinoshita J, Yamaguchi T, Moriyama H, et al. Current status of conversion surgery for stage IV gastric cancer. Surg Today. 2021;51:1736–54.

Article  Google Scholar 

Ushimaru Y, Nishikawa K, Yasuhara Y, et al. Successful laparoscopic conversion surgery for gastric cancer with para-aortic lymph node metastasis after third-line chemotherapy: a case report. Int Cancer Conf J. 2021;11:50–6.

Article  Google Scholar 

Watanabe H, Fujikawa H, Komori K, et al. Successful conversion surgery for stage IV gastric cancer after nivolumab monotherapy as third-line chemotherapy. Case Rep Gastroenterol. 2021;15:562–7.

Article  Google Scholar 

Toyota Y, Okamoto K, Tanaka N, et al. Conversion surgery of Stage IV gastric cancer with peritoneal dissemination after nivolumab. Int Cancer Conf J. 2021;10:280–4.

Article  Google Scholar 

Kumamoto T, Tomita T, Hojo Y, et al. Pathological complete response and successful conversion surgery after nivolumab therapy for Stage IV oesophagogastric junction cancer. In Vivo. 2021;35:2247–51.

Article  Google Scholar 

Matsumoto R, Arigami T, Matsushita D, et al. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report. World J Surg Oncol. 2020;18:179.

Article  Google Scholar 

Seo S, Ryu MH, Park YS, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2018;22:527–35.

Article  Google Scholar 

Shimoda Y, Fujikawa H, Komori K, et al. Prognostic factors for gastric cancer patients with one stage IV factor who underwent conversion surgery. Anticancer Res. 2021;41:1005–12.

Article  Google Scholar 

Marte G, Tufo A, Steccanella F, et al. Efficacy of surgery for the treatment of gastric cancer liver metastases: a systemic review of the literature and meta-analysis of prognostic factors. J Clin Med. 2021;10:1141.

Article  Google Scholar 

Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

Article  CAS  Google Scholar 

Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304.

Article  CAS  Google Scholar 

Kanemitsu Y, Shimizu Y, Mizusawa J, et al. Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial. J Clin Oncol. 2021;39:3789–99.

Article  CAS  Google Scholar